Relmada Therapeutics, Inc. (RLMD) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RLMD Revenue Growth
RLMD Revenue Analysis (2014–2025)
As of May 8, 2026, Relmada Therapeutics, Inc. (RLMD) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, RLMD's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including AXSM (+63.9% YoY), ALTO (-4.9% YoY), and INVA (+13.6% YoY). Compare RLMD vs AXSM →
RLMD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RLMDCurrent | $0 | - | - | - | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 ALTO | $918M | -4.9% | +0.5% | 0.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% |
RLMD Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-59,100,200 | - |
| 2024 | $0 | - | $0 | - | $-83,891,036 | - |
| 2023 | $0 | - | $0 | - | $-103,702,000 | - |
| 2022 | $0 | - | $0 | - | $-161,249,000 | - |
| 2021 | $0 | - | $0 | - | $-125,703,492 | - |
| 2020 | $0 | - | $0 | - | $-60,838,673 | - |
| 2019 | $0 | - | $0 | - | $-15,109,000 | - |
| 2018 | $0 | - | $-4,870 | - | $-12,728,000 | - |
| 2017 | $0 | - | $-2,627 | - | $-6,917,000 | - |
| 2016 | $0 | - | $-85,271 | - | $-7,219,000 | - |
See RLMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RLMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRLMD — Frequently Asked Questions
Quick answers to the most common questions about buying RLMD stock.
Is RLMD's revenue growth accelerating or slowing?
RLMD TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is RLMD's long-term revenue growth rate?
Relmada Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is RLMD's revenue distributed by segment?
RLMD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.